2017 Szent-Györgyi Prize: Michael N. Hall, Ph.D. - NFCR

2017 Award Recipient: Michael N. Hall, Ph.D.

2017 Award Recipient: Michael N. Hall, Ph.D.

Monday, May 1, 2017
6:00 pm

National Press Club
529 14th Street NW,
Washington, DC 20045

Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland

The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.

In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.

Featured Items